CN102861100A - Compound injection for treating animal respiratory tracts and preparation method thereof - Google Patents
Compound injection for treating animal respiratory tracts and preparation method thereof Download PDFInfo
- Publication number
- CN102861100A CN102861100A CN2012103801144A CN201210380114A CN102861100A CN 102861100 A CN102861100 A CN 102861100A CN 2012103801144 A CN2012103801144 A CN 2012103801144A CN 201210380114 A CN201210380114 A CN 201210380114A CN 102861100 A CN102861100 A CN 102861100A
- Authority
- CN
- China
- Prior art keywords
- injection
- compound
- respiratory tract
- compound injection
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound injection for treating animal respiratory tracts is characterized in that every 1000mL of the compound injection for treating animal respiratory tracts contains 5 to 20g of flunixin meglumine, 5 to 10g of doxycycline hydrochloride, 5 to 10g of tylosin tartrate, 1 to 5g of ribavirin, 10 to 20g of PVP-K 30, 250-600g of compound organic solvent, 0.2 to 5 g of surfactant, 10 to 40g of acid alkaline blender, 1 to 10g of antioxidant, and the balance of water for injection. The compound injection has the following advantages: (1) the product quality is stable; (2) the product efficacy is good and the action time is long; (3) the product can be conducted for industrialized mass production and the cost is low; and (4) doxycycline hydrochloride and tylosin tartrate in the products are synergistic each other, and flunixin meglumine as an antipyretic, analgesic and anti-inflammatory drug is added for relieving exterior syndrome, so that the efficacy of the product reaches or exceeds the similar product flunixin meglumine injection.
Description
Technical field
The present invention relates to a kind of compound injection and preparation method thereof, relate in particular to a kind of compound injection for the treatment of the poultry respiratory tract and preparation method thereof.
Background technology
The respiration syndrome of pig (PRDC) is commonly called as the respiratory tract disease of pig, is a kind of multiple-factor disease, by antibacterial, virus, mycoplasma, environment, stress wait one or more interactions in the factor to cause.Main diseases is original: reproductive and respiratory syndrome (PRRS), porcine circovirus (PCV-2), pseudorabies (PRV), swine influenza virus (SIV), mycoplasma (MH), atrophic rhinitis, pleuropneumonia, streptococcus, Salmonella etc.
The disease of biggest threat is first elected asthma, mycoplasma can be destroyed bronchus cilium system, can suppress fibre swing, cause the cilium atrophy even come off, the function of forfeiture whipping mucus, or cilium comes off without mucous secretion, make a lot of cause of diseases just can this take root or or smoothly by reaching pulmonary, cause the excessive even collapse of immune system pressure.The respiration syndrome of pig (PRDC) is a kind of infectious disease, if untimely treatment is easy to cause piglet dead, brings huge economic loss for pig farm and raiser.
The medicine for the treatment of in the market porcine respiratory has monomer, and compound recipe is also arranged.Its antibacterial range is narrower, and therapeutic domain is little, and the half-life is short, because antibacterial produces drug resistance, has reduced the therapeutic effect of independent use or has not had effect, thereby caused secondary infection.Cause the generation of other diseases.
Summary of the invention
The purpose of this invention is to provide a kind of compound injection for the treatment of the poultry respiratory tract, the antibacterial range of its broadening medicine prolongs its half-life, plays a kind of effect for the treatment of both the principal and secondary aspects of a disease.Make its quality and performance be better than present treatment respiratory drugs of producing.
Another object of the present invention provides the preparation method of the compound injection for the treatment of poultry respiratory tract.
The present invention is achieved like this, in the compound injection of every 1000ml treatment poultry respiratory tract, contain flunixin meglumine 5-20g, doxycycline hydrochloride 5-10g, tylosin tartrate 5-10g, ribavirin 1-5g, PVP-K30 10-20g, compound organic solvent 250-600g, surfactant 0.2-5g, soda acid blender 10-40g, antioxidant 1g-10g, surplus is water for injection.
Above-mentioned compound organic solvent is propylene glycol, glycerin methylal, dimethyl formamide.
Above-mentioned surfactant is tween 80, poloxamer.
Above-mentioned soda acid blender is hydrochloric acid, sodium hydroxide.
Above-mentioned antioxidant is sodium thiosulfate, thiourea, sodium pyrosulfite, anhydrous sodium sulfite.
Preparation method of the present invention is to carry out according to the following steps:
1. get the water for injection of total amount 30%, add flunixin meglumine, ribavirin, PVP-K30, make it be dissolved into solution fully;
2. get compounded organic solvent and be heated to 70 degrees centigrade, adding doxycycline hydrochloride, tylosin tartrate make it be dissolved into solution fully;
3. step 2 gained solution is joined in the step 1 gained solution, add again surfactant and stir with the pre-solvent antioxidant of a small amount of water;
4. inject water and be settled to 1000ml, regulate pH value 9.0～11.0 with the soda acid blender, namely obtain the present invention.
Applicable object of the present invention is: various domestic animals, other economic animals of poultry or house pet etc., its route of administration can be: intramuscular injection, subcutaneous injection, oral or other administration route.Its character is: yellow to the yellowish-brown clear liquid.The present invention has enlarged the antibacterial range of medicine, has prolonged the half-life of medicine, makes medicine can reach long-acting, slow release effect.Thereby heighten the effect of a treatment.
Advantage of the present invention is: (1) constant product quality, especially within 2 year storage period, product characteristics, content, etc. other detections still in prescribed limit; (2) prolongation of effect of selection suitable molecular weight
Agent PVP-K30: add the prolongation of effect agent, product good drug efficacy, long action time: make by behind the normal dose single administration, effective drug duration can be more than 72 hours, and general disease of domestic animals control a drug gets final product, and so largely solves the repeated multiple times medication of veterinary and brings inconvenience; (3) but the product industrialized mass, cost is lower: because in batches larger, reduced so the various losses in the production process, greatly improved the finished product rate.Mass simultaneous has also reduced greatly the other expenditure of production process to greatest extent; (4) the mutual potentiation of product doxycycline hydrochloride and tylosin tartrate, and add the flunixin meglumine antipyretic-antalgic, induce sweat in the antibiotic medicine, so all meet or exceed with similar product-flunixin meglumine inj on the product drug effect.
The specific embodiment
Embodiment one: the water for injection adding flunixin meglumine 5%, ribavirin 1%, the PVP-K30 10% that 1. get total amount 30% stir to make and are dissolved into solution fully;
2. get propylene glycol 10%, dimethyl formamide 20% is heated to 70 degrees centigrade, adds doxycycline hydrochloride 5%, tylosin tartrate 5% stirs to make and is dissolved into solution fully;
3. step 2 gained solution is joined in the step 1 gained solution, add tween 80 0.2%, add the pre-solvent anhydrous sodium sulfite 0.2% of water and stir;
4. inject water and be settled to 1000ml, survey pH value 9.0 ~ 11.0, high regulate with hydrochloric acid, low regulate with sodium hydroxide.Aseptic subpackaged, sterilization, and get final product.
Embodiment two: the water for injection adding flunixin meglumine 10%, ribavirin 2%, the PVP-K30 20% that 1. get total amount 30% stir to make and are dissolved into solution fully;
2. get propylene glycol 15%, dimethyl formamide 25% is heated to 70 degrees centigrade, adds doxycycline hydrochloride 10%, tylosin tartrate 5% stirs to make and is dissolved into solution fully;
3. step 2 gained solution is joined in the step 1 gained solution, add the pre-solvent sodium thiosulfate 0.2% of tween 80 0.2% adding water and stir;
4. inject water and be settled to 1000ml, survey pH value 9.0 ~ 11.0, high regulate with hydrochloric acid, low regulate with sodium hydroxide.Aseptic subpackaged, sterilization, and get final product.
Embodiment three: the water for injection adding flunixin meglumine 10%, ribavirin 2%, the PVP-K30 20% that 1. get total amount 30% stir to make and are dissolved into solution fully;
2. get propylene glycol 20%, dimethyl formamide 25% is heated to 70 degrees centigrade, adds doxycycline hydrochloride 5%, tylosin tartrate 10% stirs to make and is dissolved into solution fully;
3. step 2 gained solution is joined in the step 1 gained solution 1, add poloxamer 1% stirring and make fully dissolving, add the pre-solvent sodium thiosulfate 0.2% of water and stir;
4. inject water and be settled to 1000ml, survey pH value 9.0 ~ 11.0, high regulate with hydrochloric acid, low regulate with sodium hydroxide.Aseptic subpackaged, sterilization, and get final product.
Embodiment four: the anhydrous sodium sulfite of 1. getting the water for injection adding 0.2% of total amount 10% makes fully dissolving, and adding propylene glycol 20%, dimethyl formamide 25% are heated to 70 degrees centigrade of adding doxycycline hydrochloride 5%, tylosin tartrate 10% stirs to make and is dissolved into solution fully;
2. the water for injection of getting total amount 15% adds poloxamer 2% stirring makes fully dissolving, and adding PVP-K30 20% stirs and joins in the step 1 gained solution, is stirred into solution;
Water for injection adding flunixin meglumine 10%, ribavirin 2%, the stirring of 3. getting total amount 25% make and are dissolved into solution fully;
4. step 3 gained solution is joined in the step 2 gained solution, stirring injects water and is settled to 1000ml, stirs 10 minutes, surveys pH value 9.0 ~ 11.0, high regulates with hydrochloric acid, low regulates with sodium hydroxide.Aseptic subpackaged, sterilization, and get final product.
Clinical test results
1, acute toxicity test: get 30 of healthy mices, accurate weighed body weight, average weight is
20.2 g evenly is divided into 6 groups by the body weight size, (contain flunixin meglumine 10%, doxycycline hydrochloride 10%, tylosin tartrate 10%, ribavirin 2% by per kilogram of body weight 0.05ml, 0.1ml, 0.2ml, 0.4ml, 0.6ml and 1ml intramuscular injection this product respectively, below test and use same concentrations), observed 3 days after the injection, death appears in none example as a result, also finds no any untoward reaction.The result shows, it is safe that this product is used under the normal using dosage of per kilogram of body weight 0.1ml ~ 0.2ml.
2, drug metabolism test: get 10 of healthy test rabbits, accurately weighed, average weight 2.6 public affairs
Jin, all by per kilogram of body weight intramuscular injection this product 0.2ml, adopt test Cor Leporis blood respectively at 0.5h, 2h, 4h, 8h, 16h, 32h, 48h, 60h, 72h, 84h, flunixin meglumine, doxycycline hydrochloride, tylosin tartrate, ribavirin in the difference determination test rabbit blood, the result still can detect the flunixin meglumine that contains 1 ч g in every ml blood when 72h, still can detect flunixin meglumine at 84 hours in the blood.The result shows, the drug effect of this product is more than the 72h.
3, In Vitro Bacteriostasis contrast test: get flunixin meglumine inj,, two kinds of medicines are diluted with doubling dilution as test organisms with haemophilus, the minimal inhibitory concentration of this product is 1/4 of flunixin meglumine inj as a result.This result shows, shows that from laboratory test the curative effect of this product is better than flunixin meglumine inj.
4, the clinical test of pesticide effectiveness: take from 60 of right morbidity contagious pleuropneumonia pigs, be divided at random two groups by the body weight size, every group 30,47.5 kilograms of average weights, respectively by per kilogram of body weight 0.2ml intramuscular injection this product and flunixin meglumine inj (containing flunixin meglumine 10%), one time cure rate this product and notes B group are respectively 93% and 77% as a result, and the secondary cure rate is respectively 97% and 83%.The result shows, this product is better than the folk prescription flunixin meglumine inj in clinical drug effect.
5, the stability test of product: this product is stored under 40 ℃ the ambient temperature, by 6 months observations and detection, the result, product colour changes little, still in the scope of regulation, it only is 1.2% that the relative amount of flunixin meglumine descends, and the relative amount of doxycycline hydrochloride only drops to 0.3%, it only is 0.4% that the relative amount of tylosin tartrate descends, and it only is 0.3% that the relative amount of ribavirin descends.The result shows, the shelf-life of this product should be and is not less than 2 years effect duration of regulation.
Claims (6)
1. treat the compound injection of raiseeing respiratory tract for one kind, it is characterized in that containing flunixin meglumine 5-20g, doxycycline hydrochloride 5-10g, tylosin tartrate 5-10g, ribavirin 1-5g, PVP-K30 10-20g in the compound injection of every 1000ml treatment poultry respiratory tract, compound organic solvent 250-600g, surfactant 0.2-5g, soda acid blender 10-40g, antioxidant 1g-10g, surplus is water for injection.
2. the compound injection for the treatment of poultry respiratory tract according to claim 1 is characterized in that described compound organic solvent is propylene glycol, glycerin methylal, dimethyl formamide.
3. the compound injection for the treatment of poultry respiratory tract according to claim 1 is characterized in that described surfactant is tween 80, poloxamer.
4. the compound injection for the treatment of poultry respiratory tract according to claim 1 is characterized in that described soda acid blender is hydrochloric acid, sodium hydroxide.
5. the compound injection for the treatment of poultry respiratory tract according to claim 1 is characterized in that described antioxidant is sodium thiosulfate, anhydrous sodium sulfite or its mixture.
6. the preparation method of the compound injection of the described treatment poultry of a claim 1 respiratory tract is characterized in that preparation method is to carry out according to the following steps:
1. get the water for injection of total amount 30%, add flunixin meglumine, ribavirin, PVP-K30, make it be dissolved into solution fully;
2. get compounded organic solvent and be heated to 70 degrees centigrade, adding doxycycline hydrochloride, tylosin tartrate make it be dissolved into solution fully;
3. step 2 gained solution is joined in the step 1 gained solution, add again surfactant and stir with the pre-solvent antioxidant of a small amount of water;
4. inject water and be settled to 1000ml, regulate pH value 9.0～11.0 with the soda acid blender, namely obtain the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103801144A CN102861100A (en) | 2012-10-10 | 2012-10-10 | Compound injection for treating animal respiratory tracts and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103801144A CN102861100A (en) | 2012-10-10 | 2012-10-10 | Compound injection for treating animal respiratory tracts and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861100A true CN102861100A (en) | 2013-01-09 |
Family
ID=47440418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103801144A Pending CN102861100A (en) | 2012-10-10 | 2012-10-10 | Compound injection for treating animal respiratory tracts and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861100A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816166A (en) * | 2014-02-21 | 2014-05-28 | 中国兽医药品监察所 | Compound doxycycline hydrochloride injection for animals, and its preparation method |
| CN104274474A (en) * | 2014-09-12 | 2015-01-14 | 安徽天安动物药业有限公司 | Doxycycline hydrochloride injection and preparation method thereof |
| CN114042040A (en) * | 2021-12-21 | 2022-02-15 | 江西利德菲生物药业有限公司 | Long-acting flunixin meglumine injection and preparation method thereof |
| CN114404360A (en) * | 2021-12-16 | 2022-04-29 | 江西傲新生物科技有限公司 | Preparation method of flunixin meglumine injection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1572301A (en) * | 2003-06-15 | 2005-02-02 | 王玉万 | Tylosin containing antibiotic injection for animals |
-
2012
- 2012-10-10 CN CN2012103801144A patent/CN102861100A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1572301A (en) * | 2003-06-15 | 2005-02-02 | 王玉万 | Tylosin containing antibiotic injection for animals |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816166A (en) * | 2014-02-21 | 2014-05-28 | 中国兽医药品监察所 | Compound doxycycline hydrochloride injection for animals, and its preparation method |
| CN103816166B (en) * | 2014-02-21 | 2015-07-15 | 中国兽医药品监察所 | Compound doxycycline hydrochloride injection for animals, and its preparation method |
| CN104274474A (en) * | 2014-09-12 | 2015-01-14 | 安徽天安动物药业有限公司 | Doxycycline hydrochloride injection and preparation method thereof |
| CN114404360A (en) * | 2021-12-16 | 2022-04-29 | 江西傲新生物科技有限公司 | Preparation method of flunixin meglumine injection |
| CN114042040A (en) * | 2021-12-21 | 2022-02-15 | 江西利德菲生物药业有限公司 | Long-acting flunixin meglumine injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101953841B (en) | Swine eperythrozoonosis-resisting compound long-acting oxytetracycline injection and preparation method thereof | |
| CN102861100A (en) | Compound injection for treating animal respiratory tracts and preparation method thereof | |
| CN112972379A (en) | Gamithromycin emulsion, preparation method and application in preventing and treating porcine ileitis | |
| CN103143019B (en) | Compound preparation for treating porcine contagious pleuropneumonia and respiratory tract mixed infection and preparation method thereof | |
| CN102406922B (en) | Compound long-acting norfloxacin nicotinate suspension for livestock and preparation method thereof | |
| CN103432150B (en) | The compound medicine of potentiation tylosin tartrate soluble powder | |
| CN103126982A (en) | Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof | |
| CN102755337B (en) | Compound florfenicol injection and preparation method thereof | |
| CN101653448B (en) | Veterinary compound terramycin injection and preparation method thereof | |
| CN103550226B (en) | Compound sulfamonomethoxine sodium injection as well as preparation method thereof | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| CN104161761A (en) | Compound terramycin injection and preparation method thereof | |
| CN102755342B (en) | Compound paracetamol injection and preparation method thereof | |
| CN103169652A (en) | Veterinary alkaline lincomycin injection as well as preparation method and use thereof | |
| CN111759854A (en) | Injection composition for treating respiratory diseases of animals and preparation method thereof | |
| CN104288152A (en) | Compound berberine sulfate injection for veterinary use and preparation method thereof | |
| CN104906039A (en) | Suspension for injecting tilmicosin and preparation method thereof | |
| CN104606195A (en) | Compound fibrauretin injection and preparation method thereof | |
| CN102784158B (en) | Preparation method of compound synergy tylosin tartrate for veterinary injection | |
| CN103405466B (en) | Compound synergistic tylosin tartrate | |
| CN103405465A (en) | Preparation method of medicine for treating respiratory system infection of livestock and poultry | |
| CN103405463A (en) | Preparation method of synergistic tylosin tartrate soluble powder compound medicine | |
| CN105079019A (en) | Compound ivermectin vitamin B oral liquid and preparation method thereof | |
| CN102973578A (en) | Compound preparation used for controlling avian mycoplasma and Escherichia coli mixed infection, and preparation method thereof | |
| CN101822817A (en) | Compound doxycycline hydrochloride injection for treating intestinal diseases of animals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130109 |